Rapport TherapeuticsRAPP -0.60%14 Quick Ratio is 27.08 as of Mar. 2026, which is at its 10-year median of 27.08. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Rapport Therapeutics ranks better than 95.67% on this metric.
Rapport Therapeutics has a quick ratio of 27.08. It generally indicates good short-term financial strength.
The historical rank and industry rank for Rapport Therapeutics's Quick Ratio or its related term are showing as below:
RAPP'
s Quick Ratio Range Over the Past 10 Years
Min: 17.14 Med: 27.08 Max: 45.91
Current: 27.08
During the past 4 years, Rapport Therapeutics's highest Quick Ratio was 45.91. The lowest was 17.14. And the median was 27.08.
RAPP's Quick Ratio is ranked better than 95.67% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs RAPP: 27.08
Rapport Therapeutics (NAS:RAPP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Rapport Therapeutics Quick Ratio Related Terms
Rapport Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Rapport Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rapport Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Rapport Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapport Therapeutics (RAPP) has a Quick Ratio of 27.08 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Rapport Therapeutics and its competitors. This is near median its historical median of 27.08. Over the past decade, Rapport Therapeutics' Quick Ratio has ranged from 17.14 to 45.91. According to the industry distribution chart, Rapport Therapeutics ranks #61 out of 1410 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Rapport Therapeutics' Quick Ratio too high?
Rapport Therapeutics' current Quick Ratio of 27.08 is near median its 10-year median of 27.08. Over the past 10 years, this metric has ranged from a low of 17.14 to a high of 45.91. The Biotechnology industry median Quick Ratio is 3.60. Rapport Therapeutics' value of 27.08 is 652.2% above this industry median. Based on the distribution chart, Rapport Therapeutics ranks #61 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Quick Ratio compare to SION and TYRA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #61 out of 1410 companies for Quick Ratio. This places Rapport Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Rapport Therapeutics' value of 27.08 is 652.2% above this benchmark. Historically, Rapport Therapeutics' own Quick Ratio has ranged from 17.14 to 45.91 over the past decade. While the company's 10-year median is 27.08 vs. the industry median of 3.60, Rapport Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapport Therapeutics's current Quick Ratio of 27.08 is 652.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Rapport Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapport Therapeutics's current Quick Ratio is 27.08, which is near median its own 10-year median of 27.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Quick Ratio of 27.08. The current Quick Ratio is 27.08, which is near median its 10-year median of 27.08 and 652.2% above the Biotechnology industry median of 3.60. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Quick Ratio is 27.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
